- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Adrianne Appel2023-01-19T13:44:00
The Securities and Exchange Commission (SEC) asked a federal court to force Covington & Burling to comply with a subpoena seeking the law firm turn over names of about 300 clients impacted by a 2020 cyberattack.
The SEC announced Jan. 12 it filed an application to the U.S. District Court for the District of Columbia for the court to order Covington to show cause as to why it should not be compelled to comply with the agency’s subpoena, which relates to the Microsoft Hafnium cyberattack.
Microsoft announced in March 2021 some of its programs were vulnerable to hacking and that a China-based group, Hafnium, exploited the weaknesses at government agencies, businesses, and schools globally. On March 16, 2021, the SEC announced it was launching an investigation about the impact of the attack on publicly traded companies.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
Covington & Burling is leaving open the possibility of appealing a recent federal court order requiring the law firm to provide the names of hacked clients to the Securities and Exchange Commission.
The protection of customer personal data by branch offices of broker-dealers and investment advisers should be just as robust—and as well-coordinated—as protocols used by the firm’s home office, according to the Securities and Exchange Commission.
Utility company Exelon Corp announced that Colette Honorable will be named chief legal officer and corporate secretary.
German petrochemical parts supplier Aiotec agreed to pay $14.5 million to settle allegations that it engaged in a four-year conspiracy to dismantle and ship a plastics manufacturing plant owned by a U.S. company to Iran, in violation of U.S. sanctions.
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission after self-reporting that it failed to disclose material information about two cancer drugs to investors.
The U.K. Financial Conduct Authority fined the London branch of Australian-based Macquarie Bank Limited more than 13 million pounds (U.S. $16.3 million) for “serious control failures” that allowed a trader to conceal hundreds of fictitious trades over a 20-month period.
